Publicaciones en colaboración con investigadores/as de Università di Perugia (12)

2023

  1. Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

    Internal and Emergency Medicine, Vol. 18, Núm. 6, pp. 1619-1634

  2. Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents

    Seminars in Oncology, Vol. 50, Núm. 3-5, pp. 67-70

  3. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Internal Medicine, Vol. 112, pp. 29-36

2022

  1. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 796-807

  2. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain

    Journal of Medical Economics, Vol. 25, Núm. 1, pp. 840-847

  3. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  4. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study

    European Journal of Cancer, Vol. 165, pp. 136-145

  5. Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need

    Thrombosis Update, Vol. 6

2021

  1. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Cancer, Vol. 148, pp. 371-381

2020

  1. Apixaban for the treatment of venous thromboembolism associated with cancer

    New England Journal of Medicine, Vol. 382, Núm. 17, pp. 1599-1607

  2. Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients

    Haematologica, Vol. 105, Núm. 3, pp. 838-848

2018

  1. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study

    Thrombosis and Haemostasis, Vol. 118, Núm. 9, pp. 1668-1678